January 20th 2021
Although recent benefits do not pertain to all cancers and “cure” remains a relatively uncommon event, oncologists have an increasing number of molecularly targeted and immunotherapeutic strategies to employ based on objectively meaningful clinical trial outcomes.
January 18th 2021
Maurie Markman, MD, discusses remaining questions regarding human papillomavirus–negative cervical cancer.
January 10th 2021
In a pandemic, the public and its leaders yearn for relatively simple answers that can lead to solutions and forceful actions such as preventing serious infection and hospitalizations, treating active illness, and developing safe and effective vaccines quickly made available to the public.
November 18th 2020
Although PARP inhibitors are generally reasonably well tolerated, certainly compared with platinum and other routinely employed cytotoxic antineoplastic drugs, the majority of patients receiving PARP inhibitors in multiple reported clinical trials reported low-grade nausea and fatigue.
November 6th 2020
Maurie Markman, MD, discusses the utility of PARP inhibitors in ovarian cancer.
November 2nd 2020
Despite solid evidence that human papillomavirus vaccination is remarkably effective in preventing persistent infection by HPV types that are known to be responsible for more than 70% to 80% of cervical cancer cases worldwide, this strategy’s utility in substantially reducing the subsequent development of the malignancy itself remained an open question.
October 13th 2020
The fundamental objectivity of major scientifically oriented public health agencies has been called into question, while the issue of what constitutes sufficient evidence for a therapeutic strategy to be considered “standard” is also being challenged.
September 30th 2020
In the realm of medicine, we see enormous opportunities for truly novel technologies to revolutionize the health and welfare of all members of society.
September 12th 2020
Because it is likely that COVID-19 will be around for a considerable period of time, it is hoped that all involved in the clinical research establishment can view this experience as a process that needs substantial improvement.